Zacks Investment Research on MSN1d
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
Ionis Pharmaceuticals IONS announced that the European Commission (“EC”) has approved Wainzua (eplontersen) for treating ...
Business Wire2d
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis and AstraZeneca’s WAINZUA (eplontersen) has been approved in the European Union (EU ...
Pharmaceutical Technology on MSN2d
AstraZeneca and Ionis win EU approval for ATTR polyneuropathy
AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...
Ionis and AstraZeneca’s WAINZUA gets EU approval for ATTRv-PN treatment
Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca’s (AZN) WAINZUA eplontersen has been approved in the European Union EU for ...
pharmaphorum2d
EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy
AstraZeneca and Ionis Pharma have an EU green light for their Wainzua therapy for hereditary transthyretin-mediated ...
Nasdaq2d
Ionis Pharma Reports Approval Of WAINZUA In The EU - Quick Facts
(RTTNews) - Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca's WAINZUA has been approved in the European Union for the treatment of hereditary transthyretin-mediated amyloidosis ...
The Pharma Letter2d
EU nod next for ATTRv-PN drug
AstraZeneca and Ionis’ Wainzua (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary ...
pharmaphorum6d
NICE backs AZ/Ionis' Wainzua for ATTR polyneuropathy
Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with polyneuropathy associated with transthyretin ...
Investing2d
Ionis gains EU approval for amyloidosis treatment
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a $5.37 billion market cap biotechnology company, has received approval from the European Union for its treatment WAINZUA, intended for adult patients ...
Medical Dialogues22h
AstraZeneca-Ionis Pharma Wainzua approved in EU for hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...